Der neue Bioknaller!!! - 500 Beiträge pro Seite

[Millenia]

Schon einige sind auf den rasant fahrenden Zug Antisoma aufgesprungen - man träumt von einem unentdeckten Kursvervielfacher - ,die Chance hierzu hat Antisoma auf jeden Fall - es sei denn das führende Produkt Theragyn gegen Eierstockkrebs kann sich nicht behaupten.

Doch ein anderer Bioknaller aus dem Krebssektor schlummert noch und fristet sein verkanntes Leben im Schattendasein großer Biotechfirmen aus dem Krebssektor mit dem man sich in der Zukunft wohl dumm und dusslig vedienen wird...
...es sei denn man kennt diesen verkannten Star der Szene,dem schon bald eine Kursvervielfachung bevorsteht,bevor die institutionellen und Bernd Förtsch auf ihn aufmerksam werden!
Es ist ... (Fortsetzung folgt)

[nurNur]

Na....

[lukkk]

es ist bestimmt : IMCLONE !!!!

[david1]

Ich glaube enweder Trinity oder British Biotech.
Millenia,warum schreibst das nicht, ist das so geheim ???

[fuxx1.0]

Myriad ?
Cell Therapeutics?
Imclone?

[menatwork00]

Hey milenia,

sind wir hier im Kindergarten- oder was soll dieser Eintrag.

Sag es oder lass es sein! Time is money !


Gruß MH

[HerrLehmann]

Spann uns nicht auf die Folter, Millenia!

ImClone kann es nicht sein, die sind seit Okt.99 auf das 6-fache
und seit Mrz.95 auf das 180-fache gestiegen.
Für Cell Therapeutics gilt ähnliches.

Ich tippe eher auf Napro, Ligand, Synsorb.

Gruß Lehmann

[Ronny-D]

Fünfeinhalb Stunden sind rum. Kannst die Katze aus dem Sack lassen.

[genya]

Immunogen? Noven?

[WolfiPi]

Viel gerede um eine Antwort die von vornherein fest stand. Es ist Imclone , C 225 is the future. Kursziel 300 Dollar. Wer´s nicht glaubt schaut in 12 Monaten mal den Chart an.

MFG

WOLFI PI

[Schabbel]

@ Millenia und alle übrigen user:

The name is:

Aeterna Labs (WKN 902558) !!!!!!

Es sollte mich wundern, wenn es nicht so wäre.

Ich bitte Millenia um Bestätigung

Gruß:
Schabbel

[B1B2]

Wednesday November 8, 5:31 am Eastern Time

Press Release

ImClone Systems Announces Favorable Preliminary Results in Phase II Study of IMC-C225 and Irinotecan in Patients With Refractory Colorectal Carcinoma

NEW YORK--(BW HealthWire)--Nov. 8, 2000--ImClone Systems Incorporated (Nasdaq:IMCL - news) announced today favorable preliminary results from an open-label Phase II clinical study of IMC-C225 and irinotecan in patients with irinotecan-refractory colorectal carcinoma. The preliminary findings demonstrated anti-cancer activity of the combined use of IMC-C225 and irinotecan resulting in tumor shrinkage and a slowing of disease progression. IMC-C225, an investigational drug, is designed to target and block the Epidermal Growth Factor Receptor (EGFR), which is expressed on the surface of cancer cells. The majority of cases of metastatic colorectal carcinoma are positive for EGFR expression.

ImClone Systems will work with its principal investigator, Dr. Leonard Saltz, Associate Attending Physician at Memorial Sloan-Kettering Cancer Center, and other investigators for submission of the final analysis of these data for formal presentation at an upcoming scientific meeting, and for publication in a peer-reviewed journal. These data will include the final analysis of the safety and efficacy of the combination of IMC-C225 and irinotecan.

``This treatment approach of IMC-C225 and irinotecan may represent a promising step toward addressing the void in treatment for the large segment of colorectal carcinoma patients who have progressed through standard therapy,`` stated Harlan W. Waksal, M.D., Executive Vice President and Chief Operating Officer of ImClone Systems Incorporated. ``We are encouraged by these preliminary findings and are awaiting completion of our final analysis. The data are being prepared as expeditiously as possible for review by the U.S. Food and Drug Administration and we expect to submit a filing in the first half of 2001.``

The most common side effect of IMC-C225 observed in clinical studies has been an acne-like rash that resolves following cessation of treatment. Anaphylaxis has been observed infrequently during the first dose of IMC-C225. In addition, IMC-C225 does not appear to cause or enhance side effects typically observed in treatment with chemotherapy.

Colorectal carcinoma is the second most prevalent cancer in the United States. In 1999, there were approximately 130,000 cases of colorectal carcinoma diagnosed and over 55,000 deaths attributable to this type of cancer.

ImClone Systems Incorporated is advancing oncology care by developing a portfolio of targeted biologic treatments, designed to address the medical needs of patients with a variety of cancers. The Company`s three programs include growth factor blockers, cancer vaccines and angiogenesis inhibitors. ImClone Systems` strategy is to become a fully integrated biopharmaceutical company, taking its development programs from the research stage to the market. ImClone Systems is headquartered in New York City with manufacturing facilities in Somerville, New Jersey.

ImClone Systems` IMC-C225 is an investigational drug currently being evaluated in clinical trials. The determination of the safety and effectiveness of this product is subject to evaluation by the U.S. Food and Drug Administration (FDA). FDA has not reviewed or determined that the information on IMC-C225 is sufficient for approval.

Except for the historical information contained herein, the matters discussed in this news release may include forward-looking statements. Actual results may differ materially from those predicted in such forward-looking statements due to the risks and uncertainties inherent in the Company`s business, including, without limitation, risks and uncertainties in obtaining and maintaining regulatory approval, market acceptance of and continuing demand for the Company`s products, the impact of competitive products and pricing, and the Company`s ability to obtain additional financing to support its operations. The Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.